Randall W. Moreadith, MD, PhD

President and Chief Executive Officer

Randall joined Serina Therapeutics in September 2010 as President and Chief Executive Officer. Prior to joining Serina, Dr. Moreadith, 61, was Chief Development Officer at Nektar Therapeutics where he built a clinical and drug development program that successfully moved several of the company’s PEGylated small molecule drugs into the clinic, including the launch of NKTR-102 into four clinical indications (ovarian, breast, cervical and colorectal cancer) and the out-licensing efforts for NKTR-118 (approved product now known as Movantik®, Astra Zeneca and Daiichi Sankyo). He was formerly the Executive Vice President and Chief Medical Officer of Cardium Therapeutics where he led the advancement of novel DNA-based therapeutics into Phase 2b and Phase 3 late-stage development. Before Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups. Prior to that, Dr. Moreadith was co-Founder, President and Chief Operating Officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development, and one product was later approved (Ocriplasmin™). Dr. Moreadith began his career in the pharmaceutical industry as Principal Medical Officer of Quintiles, Inc., the world’s leading pharmaceutical services organization, where he led the Cardiovascular Therapeutics Group.

Dr. Moreadith has published more than 50 scientific papers and multiple book chapters, is an inventor on multiple patents, and has received numerous awards for his achievements. He received his MD from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. He received his PhD from Johns Hopkins University, and following his Fellowship in Cardiology at Duke University he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center, where he was an Established Investigator of the American Heart Association.